Asunto(s)
Buspirona/efectos adversos , Trastorno Depresivo/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Sertralina/efectos adversos , Síndrome de Abstinencia a Sustancias/etiología , Enfermedad Aguda , Trastorno Depresivo/diagnóstico , Regulación hacia Abajo/efectos de los fármacos , Femenino , Humanos , Persona de Mediana Edad , Receptores de Serotonina/efectos de los fármacos , Receptores de Serotonina/metabolismo , Serotonina/metabolismo , Síndrome de Abstinencia a Sustancias/metabolismo , SíndromeRESUMEN
The lack of culturally appropriate psychometric instruments for the assessment of cognitive and emotional functioning in minority populations has been a concern often discussed in the assessment literature. With the increased focus on the measurement of outcome in mental health treatment, the lack of appropriate instruments for minorities has become readily apparent in this venue as well. We report on the Spanish translation of a brief and reliable measure of psychological health and well-being that has been shown to be sensitive to treatment outcomes. The original and Spanish translated versions of this measure are highly correlated, providing clinicians and organizations with a instrument that can be used for assessment of psychological well-being and treatment outcomes with Hispanic patients.
Asunto(s)
Hispánicos o Latinos/psicología , Trastornos Mentales/psicología , Servicios de Salud Mental , Evaluación de Resultado en la Atención de Salud , Escalas de Valoración Psiquiátrica , Aculturación , Adulto , Factores de Edad , Femenino , Humanos , Masculino , Trastornos Mentales/diagnóstico , Pruebas Psicológicas/estadística & datos numéricos , Psicometría , Valores de Referencia , Sensibilidad y Especificidad , Factores SexualesRESUMEN
The expected rise in prevalence rates of Alzheimer's disease over the next several decades has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.
